Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACTS: eltrombopag with rabbit ATG and cyclosporine A in treatment-naive severe aplastic anemia
2024-000602-14Phase 2
- Sponsor
- Novartis
- Start
- May 2025
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag, antithymocyte globulin rabbit and cyclosporine in aplastic anemia, sponsored by Novartis. Primary endpoint: Complete response rate at Week 26.
02
Drugs
eltrombopagantithymocyte globulin rabbitcyclosporine
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on 2024-000602-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000602-14.